Nordic Nanovector

330 articles with Nordic Nanovector

• Nordic Nanovector ASA - Extraordinary General Meeting Held

  12/20/2017

  An Extraordinary General Meeting of Nordic Nanovector was held today on 20 December 2017 in Oslo, Norway.

• Betalutin Shows Strong Clinical Profile in Relapsed/Refractory Indolent NHL and Follicular Lymphoma

  12/11/2017

  The updated data continue to highlight Betalutin's strong clinical profile as a single agent for treatment of R/R iNHL, and particularly of 3L FL.

• Nordic Nanovector: Notice of Extraordinary General Meeting

  11/30/2017

  The Board of Directors of Nordic Nanovector call for an Extraordinary General Meeting to be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo on 20 December 2017 at 10:30 CET.

• Nordic Nanovector ASA - Results for the Third Quarter 2017

  11/22/2017

  PARADIGME is designed to generate the clinical data needed to support the filing of the best Betalutin dosage regimen for this patient population.

• Nordic Nanovector ASA - Financial Calendar

  11/15/2017

  The time and location of the presentations will be announced in due time.

• Nordic Nanovector: Protocol Amendment Filed in the UK to Enable Initiation of Phase II PARADIGME

  11/8/2017

  Nordic Nanovector notes that information relating to an application for a Protocol Amendment to the LYMRIT 37-01 study, for the planned pivotal Phase IIb clinical trial PARADIGME to evaluate Betalutin in recurrent/relapsed follicular lymphoma has been published by MHRA.

• Nordic Nanovector: Updated Results From Phase I/II Trial of Betalutin in Non-Hodgkin Lymphoma to be Presented at ASH in December

  11/1/2017

  The dataset includes 55 evaluable patients. Data from patients receiving the two most promising dosing regimens in the Phase II expansion cohorts

• Nordic Nanovector: Share Capital Increase Registered

  8/30/2017

• Nordic Nanovector - Results For Second Quarter And First Half Year 2017

  8/23/2017

• Nordic Nanovector: Invitation To Second Quarter 2017 Results Presentation And Webcast

  8/16/2017

• Nordic Nanovector Appoints Dr. Reza Safaei As Head Of Medical Affairs

  8/2/2017

• Nordic Nanovector: Increase Of Share Capital/Mandatory Notification Of Trade

  7/10/2017

• Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider

  7/5/2017

• Nordic Nanovector: Mandatory Notification Of Trade - Primary Insider

  6/22/2017

• Nordic Nanovector Release: Single Dose Betalutin Continues To Show Promising Efficacy And Safety In Recurrent Indolent NHL Patients

  6/14/2017

• Nordic Nanovector Release: Invitation To Conference Call For Updated Clinical Trial Results Reported At The International Conference On Malignant Lymphoma

  6/13/2017

• Nordic Nanovector To Be Included In Oslo Børs OBX Index

  6/9/2017

• Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line

  6/8/2017

• Nordic Nanovector: Allocation Of Restricted Stock Units (RSUs) To The Board Of Directors

  6/2/2017

• Nordic Nanovector - Results For First Quarter 2017

  5/24/2017